Goldlust, Samuel A <br/><br/>
Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.  [electronic resource] 

 -  Journal of neuro-oncology  Apr 2012 
 - 407-11 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1573-7373 
<br/><br/><label>Standard No.: </label>10.1007/s11060-011-0768-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Bevacizumab<br/>Brain--drug effects<br/>Brain Neoplasms--drug therapy<br/>Female<br/>Follow-Up Studies<br/>Glioblastoma--drug therapy<br/>Humans<br/>Magnetic Resonance Imaging<br/>Male<br/>Middle Aged<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors